In adults with overweight or obesity, 84.2% preferred a hypothetical semaglutide-like profile versus 15.8% for an orforglipron-like profile.
In plain wordsAdults with overweight or obesity preferred a hypothetical semaglutide-like profile over an orforglipron-like profile in the experiment.
- Peptide
- Semaglutide
- Outcome
- IncreaseDCE profile preference
- Study
n = 800
- Comparator
- Hypothetical orforglipron-like profile
- Outcome group
- Patient-reported outcomes · Whole body
Measurements
- DCE preference
- 84.2%
- semaglutide-like profile
- DCE preference
- 15.8%
- orforglipron-like profile
Source sentences
There was a preference for 1 OM profile (Treatment A-a hypothetical oral semaglutide-like profile) over the alternative OM profile (Treatment B-a hypothetical orforglipron-like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed-choice question (90.0% vs. 10.0%).
2 context sentences(design, population, supporting numbers)
US adults with obesity or overweight and ≥ 1 obesity-related complication completed an online survey including a discrete-choice experiment (DCE) in October-November 2025.
In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.